| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 23 | 2024 | 306 | 4.170 |
Why?
|
| Glioblastoma | 16 | 2022 | 156 | 3.760 |
Why?
|
| Hydrocephalus, Normal Pressure | 5 | 2023 | 14 | 3.290 |
Why?
|
| Hydrocephalus | 3 | 2023 | 42 | 1.790 |
Why?
|
| Cervical Vertebrae | 3 | 2024 | 103 | 1.690 |
Why?
|
| Spinal Fusion | 3 | 2024 | 127 | 1.570 |
Why?
|
| MicroRNAs | 7 | 2019 | 623 | 1.450 |
Why?
|
| Ventriculoperitoneal Shunt | 4 | 2019 | 30 | 1.300 |
Why?
|
| Meningeal Neoplasms | 7 | 2023 | 57 | 1.220 |
Why?
|
| Aneurysm, Ruptured | 3 | 2023 | 72 | 1.220 |
Why?
|
| Glioma | 5 | 2017 | 104 | 1.170 |
Why?
|
| Diskectomy | 3 | 2024 | 29 | 1.100 |
Why?
|
| Meningioma | 7 | 2014 | 58 | 1.100 |
Why?
|
| Radiosurgery | 4 | 2022 | 61 | 1.020 |
Why?
|
| Humans | 108 | 2024 | 60913 | 1.010 |
Why?
|
| Cranial Irradiation | 2 | 2024 | 10 | 0.970 |
Why?
|
| Anatomic Landmarks | 1 | 2024 | 9 | 0.950 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2024 | 21 | 0.940 |
Why?
|
| Wounds, Gunshot | 2 | 2022 | 53 | 0.940 |
Why?
|
| Trephining | 1 | 2024 | 3 | 0.930 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 74 | 0.900 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2023 | 7 | 0.900 |
Why?
|
| Adenylate Kinase | 1 | 2023 | 15 | 0.880 |
Why?
|
| Self-Injurious Behavior | 1 | 2024 | 47 | 0.880 |
Why?
|
| Cancer Survivors | 1 | 2024 | 80 | 0.860 |
Why?
|
| Neoplastic Stem Cells | 3 | 2015 | 203 | 0.850 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 248 | 0.850 |
Why?
|
| Neurosurgery | 1 | 2023 | 30 | 0.850 |
Why?
|
| Membrane Proteins | 4 | 2021 | 850 | 0.820 |
Why?
|
| Intracranial Aneurysm | 2 | 2023 | 344 | 0.810 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2023 | 82 | 0.780 |
Why?
|
| Neurons | 11 | 2004 | 865 | 0.780 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2023 | 275 | 0.770 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2021 | 4 | 0.760 |
Why?
|
| Fibrinolysin | 1 | 2021 | 5 | 0.760 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2021 | 5 | 0.760 |
Why?
|
| Drug Delivery Systems | 2 | 2022 | 312 | 0.760 |
Why?
|
| Cell Proliferation | 3 | 2019 | 947 | 0.740 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2014 | 16 | 0.730 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2022 | 78 | 0.720 |
Why?
|
| Animals | 52 | 2023 | 19802 | 0.710 |
Why?
|
| Stuttering | 1 | 2019 | 3 | 0.680 |
Why?
|
| ErbB Receptors | 5 | 2012 | 114 | 0.670 |
Why?
|
| Male | 40 | 2024 | 28424 | 0.640 |
Why?
|
| Mice | 31 | 2023 | 10338 | 0.620 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 649 | 0.620 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 309 | 0.610 |
Why?
|
| Cell Movement | 5 | 2013 | 427 | 0.600 |
Why?
|
| Anesthesia, Obstetrical | 10 | 1993 | 24 | 0.600 |
Why?
|
| Adult | 36 | 2024 | 16211 | 0.580 |
Why?
|
| Serotonin | 7 | 2018 | 63 | 0.570 |
Why?
|
| Female | 57 | 2024 | 31706 | 0.540 |
Why?
|
| Proteomics | 5 | 2005 | 265 | 0.540 |
Why?
|
| Dual-Specificity Phosphatases | 2 | 2014 | 7 | 0.530 |
Why?
|
| Craniotomy | 2 | 2015 | 20 | 0.520 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 19 | 0.510 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 1389 | 0.510 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2015 | 5 | 0.500 |
Why?
|
| Cerebrum | 1 | 2015 | 16 | 0.500 |
Why?
|
| Wakefulness | 1 | 2015 | 42 | 0.490 |
Why?
|
| Middle Aged | 29 | 2024 | 16857 | 0.480 |
Why?
|
| Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 3 | 0.480 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2014 | 6 | 0.480 |
Why?
|
| rho-Associated Kinases | 1 | 2014 | 11 | 0.460 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 19 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2015 | 302 | 0.440 |
Why?
|
| Protein Biosynthesis | 3 | 2014 | 297 | 0.430 |
Why?
|
| Brain | 6 | 2023 | 1512 | 0.430 |
Why?
|
| Alcoholism | 1 | 2016 | 310 | 0.430 |
Why?
|
| Alternative Splicing | 2 | 2012 | 124 | 0.420 |
Why?
|
| Glasgow Coma Scale | 2 | 2023 | 44 | 0.420 |
Why?
|
| Apoptosis | 8 | 2010 | 1044 | 0.410 |
Why?
|
| Aged | 23 | 2023 | 13873 | 0.410 |
Why?
|
| DNA Damage | 4 | 2004 | 288 | 0.410 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 9 | 0.400 |
Why?
|
| Multigene Family | 2 | 2010 | 92 | 0.400 |
Why?
|
| Anesthesia, Epidural | 6 | 1993 | 24 | 0.400 |
Why?
|
| DNA Copy Number Variations | 4 | 2019 | 67 | 0.390 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2012 | 6 | 0.390 |
Why?
|
| Chromosomal Instability | 1 | 2012 | 20 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 320 | 0.380 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2010 | 48 | 0.380 |
Why?
|
| Salvage Therapy | 3 | 2017 | 74 | 0.370 |
Why?
|
| Blood-Brain Barrier | 2 | 2022 | 81 | 0.370 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2019 | 83 | 0.370 |
Why?
|
| History, 20th Century | 2 | 2024 | 231 | 0.370 |
Why?
|
| Treatment Outcome | 10 | 2023 | 5347 | 0.370 |
Why?
|
| Retrospective Studies | 10 | 2023 | 6192 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 2073 | 0.350 |
Why?
|
| Mice, Nude | 11 | 2013 | 260 | 0.350 |
Why?
|
| Blotting, Western | 7 | 2012 | 596 | 0.350 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 761 | 0.340 |
Why?
|
| Neoplasms | 3 | 2014 | 1269 | 0.340 |
Why?
|
| RNA, Messenger | 11 | 2011 | 1474 | 0.330 |
Why?
|
| Proteins | 6 | 2023 | 741 | 0.330 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 49 | 0.330 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 2401 | 0.330 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 420 | 0.330 |
Why?
|
| Oncogenes | 1 | 2010 | 68 | 0.330 |
Why?
|
| Wnt Proteins | 1 | 2010 | 91 | 0.330 |
Why?
|
| Transcription Factors | 3 | 2010 | 1486 | 0.320 |
Why?
|
| Young Adult | 8 | 2024 | 4430 | 0.320 |
Why?
|
| Travel-Related Illness | 2 | 2019 | 3 | 0.320 |
Why?
|
| Gene Deletion | 3 | 2021 | 297 | 0.310 |
Why?
|
| Immunohistochemistry | 10 | 2012 | 859 | 0.310 |
Why?
|
| Synapses | 4 | 1995 | 180 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 484 | 0.310 |
Why?
|
| Caspases | 3 | 2002 | 166 | 0.300 |
Why?
|
| Hypopharynx | 1 | 2008 | 4 | 0.300 |
Why?
|
| Laryngoscopy | 2 | 2008 | 61 | 0.300 |
Why?
|
| Clindamycin | 1 | 2008 | 13 | 0.300 |
Why?
|
| Pharyngeal Diseases | 1 | 2008 | 10 | 0.300 |
Why?
|
| Osteonecrosis | 1 | 2008 | 4 | 0.300 |
Why?
|
| Glycoproteins | 4 | 2012 | 192 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 747 | 0.300 |
Why?
|
| Capsules | 1 | 2008 | 34 | 0.290 |
Why?
|
| HIV | 1 | 2008 | 69 | 0.290 |
Why?
|
| Child, Preschool | 7 | 2024 | 1880 | 0.280 |
Why?
|
| MAP Kinase Signaling System | 3 | 2010 | 201 | 0.280 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2013 | 38 | 0.280 |
Why?
|
| Travel | 2 | 2019 | 33 | 0.280 |
Why?
|
| Mutation | 5 | 2023 | 2485 | 0.280 |
Why?
|
| Propensity Score | 3 | 2023 | 138 | 0.280 |
Why?
|
| Receptor, EphA2 | 1 | 2006 | 2 | 0.270 |
Why?
|
| Signal Transduction | 6 | 2015 | 2897 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2004 | 98 | 0.270 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2007 | 57 | 0.270 |
Why?
|
| Gene Dosage | 3 | 2011 | 60 | 0.270 |
Why?
|
| Neurosurgical Procedures | 2 | 2023 | 94 | 0.270 |
Why?
|
| Genome, Human | 3 | 2011 | 222 | 0.270 |
Why?
|
| Anesthesia, Spinal | 4 | 1991 | 29 | 0.270 |
Why?
|
| Gene Expression Profiling | 7 | 2015 | 721 | 0.260 |
Why?
|
| Radiography | 2 | 2023 | 520 | 0.250 |
Why?
|
| Protein Binding | 3 | 2021 | 1585 | 0.250 |
Why?
|
| Genes, p53 | 3 | 2004 | 53 | 0.250 |
Why?
|
| Transfection | 7 | 2010 | 677 | 0.250 |
Why?
|
| Thyroid Cartilage | 1 | 2024 | 1 | 0.240 |
Why?
|
| Hyoid Bone | 1 | 2024 | 3 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 302 | 0.240 |
Why?
|
| Central Nervous System | 2 | 2002 | 192 | 0.240 |
Why?
|
| Down-Regulation | 3 | 2021 | 309 | 0.240 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 5289 | 0.240 |
Why?
|
| Pain, Intractable | 1 | 2004 | 4 | 0.230 |
Why?
|
| Stents | 3 | 2013 | 459 | 0.230 |
Why?
|
| Trigeminal Neuralgia | 1 | 2004 | 8 | 0.230 |
Why?
|
| Neoplasm Transplantation | 8 | 2013 | 162 | 0.230 |
Why?
|
| Gene Expression Regulation | 5 | 2023 | 1549 | 0.230 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 29 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2006 | 205 | 0.230 |
Why?
|
| Skull | 1 | 2024 | 57 | 0.230 |
Why?
|
| Adolescent | 8 | 2024 | 6041 | 0.220 |
Why?
|
| Choroid Plexus | 1 | 2023 | 16 | 0.220 |
Why?
|
| RNA Interference | 3 | 2014 | 593 | 0.220 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2008 | 62 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 2 | 2005 | 135 | 0.220 |
Why?
|
| Mass Spectrometry | 2 | 2004 | 297 | 0.210 |
Why?
|
| Hippocampus | 2 | 1998 | 250 | 0.210 |
Why?
|
| Ear, Inner | 1 | 2023 | 16 | 0.210 |
Why?
|
| Angioplasty | 2 | 2013 | 47 | 0.210 |
Why?
|
| Vasospasm, Intracranial | 1 | 2023 | 25 | 0.210 |
Why?
|
| Child | 7 | 2024 | 4380 | 0.210 |
Why?
|
| Cesarean Section | 9 | 1991 | 97 | 0.200 |
Why?
|
| Parkinson Disease | 2 | 2019 | 128 | 0.200 |
Why?
|
| Rats | 11 | 2014 | 1918 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2024 | 534 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 10 | 2012 | 457 | 0.200 |
Why?
|
| Didanosine | 1 | 2002 | 3 | 0.200 |
Why?
|
| Retinoblastoma Protein | 2 | 2014 | 37 | 0.200 |
Why?
|
| Bupivacaine | 3 | 1993 | 33 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2023 | 1088 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 3 | 2010 | 139 | 0.200 |
Why?
|
| Adenosine Deaminase | 1 | 2002 | 17 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 531 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2019 | 11 | 0.190 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2023 | 93 | 0.190 |
Why?
|
| Injury Severity Score | 1 | 2022 | 103 | 0.190 |
Why?
|
| Microsurgery | 1 | 2022 | 52 | 0.190 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 76 | 0.190 |
Why?
|
| Prodrugs | 1 | 2002 | 35 | 0.190 |
Why?
|
| Cell Division | 8 | 2010 | 444 | 0.190 |
Why?
|
| Enzyme Activation | 3 | 2014 | 359 | 0.190 |
Why?
|
| Geologic Sediments | 1 | 2001 | 5 | 0.190 |
Why?
|
| Soil Pollutants | 1 | 2001 | 25 | 0.180 |
Why?
|
| Protein Kinases | 1 | 2002 | 143 | 0.180 |
Why?
|
| Phenotype | 4 | 2015 | 1157 | 0.180 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2001 | 17 | 0.180 |
Why?
|
| Soil | 1 | 2001 | 26 | 0.180 |
Why?
|
| Raphe Nuclei | 3 | 1995 | 6 | 0.180 |
Why?
|
| Cell Adhesion | 3 | 2019 | 208 | 0.180 |
Why?
|
| CDC2 Protein Kinase | 2 | 2014 | 33 | 0.180 |
Why?
|
| Cells, Cultured | 9 | 2002 | 2106 | 0.180 |
Why?
|
| HIV Infections | 1 | 2008 | 928 | 0.180 |
Why?
|
| Basal Ganglia Hemorrhage | 1 | 2020 | 2 | 0.180 |
Why?
|
| Protein Domains | 1 | 2021 | 142 | 0.180 |
Why?
|
| Water Pollutants, Chemical | 1 | 2001 | 41 | 0.180 |
Why?
|
| Isotonic Solutions | 2 | 1991 | 15 | 0.180 |
Why?
|
| Diagnosis, Differential | 4 | 2008 | 932 | 0.170 |
Why?
|
| Chemical Hazard Release | 1 | 2020 | 1 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 61 | 0.170 |
Why?
|
| Catheter Obstruction | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 56 | 0.170 |
Why?
|
| Ammonia | 1 | 2020 | 15 | 0.170 |
Why?
|
| HeLa Cells | 1 | 2021 | 531 | 0.170 |
Why?
|
| Vocal Cord Paralysis | 1 | 2019 | 11 | 0.170 |
Why?
|
| Spinal Puncture | 1 | 2019 | 16 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 2 | 1990 | 86 | 0.170 |
Why?
|
| Pregnancy | 13 | 1993 | 2375 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 664 | 0.170 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 1134 | 0.170 |
Why?
|
| Memory, Short-Term | 1 | 2000 | 59 | 0.160 |
Why?
|
| Thalamus | 1 | 2000 | 64 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 196 | 0.160 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 31 | 0.160 |
Why?
|
| Nanotubes, Carbon | 1 | 2019 | 19 | 0.160 |
Why?
|
| Lung Neoplasms | 4 | 2013 | 585 | 0.160 |
Why?
|
| Oncogene Protein v-akt | 1 | 2019 | 16 | 0.160 |
Why?
|
| Lipids | 1 | 2021 | 306 | 0.160 |
Why?
|
| Drainage | 1 | 2019 | 150 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2019 | 166 | 0.160 |
Why?
|
| Brain Ischemia | 1 | 2023 | 402 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 99 | 0.160 |
Why?
|
| Language | 1 | 2000 | 138 | 0.150 |
Why?
|
| Reoperation | 1 | 2019 | 270 | 0.150 |
Why?
|
| Diarrhea | 2 | 2019 | 76 | 0.150 |
Why?
|
| Melatonin | 1 | 2018 | 66 | 0.150 |
Why?
|
| Dacarbazine | 2 | 2015 | 20 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 170 | 0.150 |
Why?
|
| Genomics | 2 | 2012 | 321 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2015 | 33 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 183 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 1999 | 106 | 0.150 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2006 | 99 | 0.150 |
Why?
|
| Environmental Exposure | 1 | 2020 | 216 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 73 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 83 | 0.150 |
Why?
|
| RNA | 1 | 2021 | 405 | 0.150 |
Why?
|
| Re-Irradiation | 1 | 2017 | 2 | 0.150 |
Why?
|
| Military Personnel | 1 | 2019 | 97 | 0.150 |
Why?
|
| Thiophenes | 2 | 2014 | 31 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2015 | 877 | 0.140 |
Why?
|
| Bevacizumab | 1 | 2017 | 58 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 196 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2018 | 139 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 209 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2018 | 139 | 0.140 |
Why?
|
| Time Factors | 6 | 2017 | 3661 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 244 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 43 | 0.140 |
Why?
|
| Cell Growth Processes | 2 | 2007 | 37 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 3 | 2011 | 397 | 0.140 |
Why?
|
| Pregnancy Complications | 2 | 1993 | 392 | 0.130 |
Why?
|
| Brain Injuries | 1 | 2018 | 137 | 0.130 |
Why?
|
| Base Sequence | 3 | 2010 | 1310 | 0.130 |
Why?
|
| In Vitro Techniques | 4 | 2012 | 476 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2018 | 192 | 0.130 |
Why?
|
| Analgesia, Epidural | 3 | 1990 | 31 | 0.130 |
Why?
|
| Sleep | 1 | 2018 | 224 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 296 | 0.130 |
Why?
|
| Infant | 6 | 2020 | 1546 | 0.130 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cell Death | 3 | 2002 | 272 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 42 | 0.120 |
Why?
|
| Peptides | 2 | 2012 | 551 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 50 | 0.120 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2014 | 13 | 0.120 |
Why?
|
| Self Administration | 1 | 2014 | 47 | 0.120 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 112 | 0.120 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 65 | 0.120 |
Why?
|
| Stroke | 3 | 2013 | 1145 | 0.120 |
Why?
|
| Hospitalization | 3 | 2023 | 1321 | 0.120 |
Why?
|
| Mice, Transgenic | 6 | 2008 | 1226 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2013 | 218 | 0.120 |
Why?
|
| E2F Transcription Factors | 1 | 2014 | 16 | 0.110 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2014 | 16 | 0.110 |
Why?
|
| Ischemic Attack, Transient | 2 | 2013 | 92 | 0.110 |
Why?
|
| Brain Mapping | 1 | 2015 | 228 | 0.110 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2014 | 22 | 0.110 |
Why?
|
| Tumor Burden | 2 | 2013 | 62 | 0.110 |
Why?
|
| Animals, Newborn | 5 | 1996 | 232 | 0.110 |
Why?
|
| Actomyosin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Glucosides | 1 | 2014 | 13 | 0.110 |
Why?
|
| Protein Subunits | 1 | 2014 | 165 | 0.110 |
Why?
|
| Glutamates | 1 | 1994 | 14 | 0.110 |
Why?
|
| Exosomes | 1 | 2014 | 44 | 0.110 |
Why?
|
| Type C Phospholipases | 1 | 1994 | 33 | 0.110 |
Why?
|
| Cell Nucleolus | 1 | 2014 | 68 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 366 | 0.110 |
Why?
|
| Disease Progression | 3 | 2017 | 1126 | 0.110 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 43 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 67 | 0.110 |
Why?
|
| NADPH Dehydrogenase | 1 | 1993 | 4 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 144 | 0.110 |
Why?
|
| Cytoplasm | 1 | 2014 | 274 | 0.110 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 1990 | 34 | 0.110 |
Why?
|
| Catecholamines | 1 | 1993 | 31 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2013 | 83 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 1993 | 17 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 340 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 933 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1186 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2004 | 42 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2008 | 100 | 0.100 |
Why?
|
| Perioperative Period | 1 | 2012 | 20 | 0.100 |
Why?
|
| Electrophysiology | 3 | 2000 | 89 | 0.100 |
Why?
|
| Transplantation, Heterologous | 4 | 2010 | 225 | 0.100 |
Why?
|
| AC133 Antigen | 1 | 2012 | 5 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 63 | 0.100 |
Why?
|
| Fourth Ventricle | 1 | 2012 | 3 | 0.100 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 8 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 115 | 0.100 |
Why?
|
| Pain, Postoperative | 3 | 1990 | 134 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 380 | 0.100 |
Why?
|
| Risk Factors | 5 | 2018 | 5158 | 0.100 |
Why?
|
| Glucose | 1 | 2015 | 448 | 0.100 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2012 | 24 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 211 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2012 | 343 | 0.100 |
Why?
|
| Genes, myc | 3 | 2004 | 19 | 0.100 |
Why?
|
| Astrocytoma | 2 | 2009 | 12 | 0.100 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ephedrine | 1 | 1991 | 3 | 0.090 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1991 | 5 | 0.090 |
Why?
|
| DNA Modification Methylases | 1 | 2011 | 18 | 0.090 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 37 | 0.090 |
Why?
|
| Fetal Blood | 1 | 1991 | 73 | 0.090 |
Why?
|
| Pituitary Gland | 1 | 1990 | 50 | 0.090 |
Why?
|
| DNA Primers | 2 | 2010 | 291 | 0.090 |
Why?
|
| Meperidine | 1 | 1990 | 4 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2019 | 3188 | 0.090 |
Why?
|
| Snail Family Transcription Factors | 1 | 2010 | 25 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2012 | 642 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 333 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 857 | 0.090 |
Why?
|
| Scoliosis | 1 | 1990 | 9 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 670 | 0.090 |
Why?
|
| Adenoviridae | 2 | 2002 | 120 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 4 | 2008 | 108 | 0.090 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 48 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 9 | 0.090 |
Why?
|
| Shivering | 1 | 1990 | 1 | 0.090 |
Why?
|
| Databases, Nucleic Acid | 1 | 2010 | 8 | 0.090 |
Why?
|
| Ganglia, Sympathetic | 1 | 1989 | 5 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 203 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 81 | 0.080 |
Why?
|
| Cell Survival | 2 | 2002 | 562 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 17 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2002 | 3222 | 0.080 |
Why?
|
| Obstetric Labor Complications | 1 | 1990 | 26 | 0.080 |
Why?
|
| Myotonic Dystrophy | 1 | 1990 | 10 | 0.080 |
Why?
|
| Fentanyl | 4 | 1993 | 74 | 0.080 |
Why?
|
| Gliosis | 1 | 1989 | 27 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 194 | 0.080 |
Why?
|
| Immunoblotting | 2 | 2004 | 189 | 0.080 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 80 | 0.080 |
Why?
|
| beta Catenin | 1 | 2010 | 85 | 0.080 |
Why?
|
| Abdomen | 1 | 1990 | 92 | 0.080 |
Why?
|
| Hamartoma | 1 | 1989 | 7 | 0.080 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2009 | 5 | 0.080 |
Why?
|
| Fetal Organ Maturity | 1 | 1989 | 2 | 0.080 |
Why?
|
| GTPase-Activating Proteins | 1 | 2010 | 64 | 0.080 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2015 | 20 | 0.080 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 8 | 0.080 |
Why?
|
| Growth Substances | 1 | 1989 | 35 | 0.080 |
Why?
|
| Central Nervous System Diseases | 1 | 1989 | 57 | 0.080 |
Why?
|
| Urethral Obstruction | 1 | 1989 | 6 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 1989 | 48 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 1989 | 21 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 461 | 0.080 |
Why?
|
| Astrocytes | 1 | 1989 | 117 | 0.080 |
Why?
|
| Anesthesia, General | 1 | 1989 | 46 | 0.080 |
Why?
|
| Calcinosis | 1 | 2009 | 80 | 0.080 |
Why?
|
| Cell Line | 2 | 2012 | 2014 | 0.080 |
Why?
|
| Tenascin | 1 | 2008 | 4 | 0.080 |
Why?
|
| Fetus | 1 | 1989 | 98 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 1989 | 140 | 0.080 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 197 | 0.080 |
Why?
|
| Ependyma | 2 | 2023 | 9 | 0.080 |
Why?
|
| Rats, Inbred Strains | 4 | 1995 | 150 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 1989 | 157 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2009 | 466 | 0.070 |
Why?
|
| Age Factors | 3 | 2018 | 1548 | 0.070 |
Why?
|
| Cattle | 2 | 2002 | 307 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2010 | 279 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 409 | 0.070 |
Why?
|
| Blotting, Northern | 4 | 2008 | 148 | 0.070 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 172 | 0.070 |
Why?
|
| Respiration | 1 | 1988 | 95 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2008 | 66 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2014 | 293 | 0.070 |
Why?
|
| Zebrafish | 1 | 2010 | 324 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 1989 | 159 | 0.070 |
Why?
|
| Myocardial Infarction | 2 | 1990 | 874 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 1518 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 138 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 154 | 0.070 |
Why?
|
| Pandemics | 2 | 2022 | 636 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 632 | 0.060 |
Why?
|
| Proteome | 2 | 2004 | 142 | 0.060 |
Why?
|
| Annexins | 3 | 1990 | 9 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 1988 | 192 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2005 | 25 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 1989 | 455 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1303 | 0.060 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2015 | 19 | 0.060 |
Why?
|
| Trauma, Nervous System | 1 | 2005 | 1 | 0.060 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 1994 | 33 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1975 | 0.060 |
Why?
|
| Motor Neuron Disease | 1 | 2005 | 30 | 0.060 |
Why?
|
| Trigeminal Nerve Injuries | 1 | 2004 | 1 | 0.060 |
Why?
|
| Algorithms | 2 | 2011 | 1016 | 0.060 |
Why?
|
| Glutamine | 1 | 2005 | 47 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2004 | 30 | 0.060 |
Why?
|
| Phalloidine | 1 | 2004 | 4 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 285 | 0.060 |
Why?
|
| Electrodes, Implanted | 1 | 2004 | 38 | 0.060 |
Why?
|
| Free Radicals | 1 | 2004 | 18 | 0.060 |
Why?
|
| Prognosis | 3 | 2014 | 1630 | 0.060 |
Why?
|
| Herpes Zoster | 1 | 2004 | 24 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2004 | 82 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 690 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 1989 | 510 | 0.060 |
Why?
|
| Lung | 1 | 1989 | 904 | 0.060 |
Why?
|
| Sex Factors | 2 | 2018 | 984 | 0.060 |
Why?
|
| Down Syndrome | 1 | 2005 | 50 | 0.060 |
Why?
|
| Feces | 2 | 2014 | 97 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2004 | 164 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2004 | 54 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1994 | 78 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 90 | 0.050 |
Why?
|
| tau Proteins | 1 | 2005 | 190 | 0.050 |
Why?
|
| Petrous Bone | 1 | 2023 | 3 | 0.050 |
Why?
|
| Fractals | 1 | 2023 | 8 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2023 | 35 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 119 | 0.050 |
Why?
|
| Temporal Bone | 1 | 2023 | 37 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 338 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 75 | 0.050 |
Why?
|
| Ticlopidine | 2 | 2013 | 47 | 0.050 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 14 | 0.050 |
Why?
|
| Camptothecin | 1 | 2002 | 23 | 0.050 |
Why?
|
| Oxygen | 1 | 2004 | 315 | 0.050 |
Why?
|
| Microscopy, Electron | 2 | 1995 | 249 | 0.050 |
Why?
|
| Nervous System | 1 | 2002 | 69 | 0.050 |
Why?
|
| Neurosciences | 1 | 2002 | 29 | 0.050 |
Why?
|
| Survival Rate | 2 | 2014 | 813 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2014 | 290 | 0.050 |
Why?
|
| Cilia | 1 | 2023 | 160 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 87 | 0.050 |
Why?
|
| Injections, Epidural | 3 | 1990 | 6 | 0.050 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2001 | 19 | 0.050 |
Why?
|
| S Phase | 1 | 2001 | 76 | 0.050 |
Why?
|
| Anesthesia, Intravenous | 2 | 1993 | 15 | 0.050 |
Why?
|
| Environmental Pollution | 1 | 2001 | 12 | 0.050 |
Why?
|
| Humic Substances | 1 | 2001 | 4 | 0.050 |
Why?
|
| Aspirin | 2 | 2013 | 173 | 0.050 |
Why?
|
| Neurology | 1 | 2001 | 35 | 0.050 |
Why?
|
| DNA Restriction Enzymes | 1 | 2001 | 35 | 0.050 |
Why?
|
| Calorimetry | 1 | 2001 | 40 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2023 | 283 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2642 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2022 | 119 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2001 | 50 | 0.050 |
Why?
|
| Adsorption | 1 | 2001 | 84 | 0.050 |
Why?
|
| Labor, Obstetric | 2 | 1992 | 39 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2004 | 944 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2002 | 368 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2000 | 16 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2012 | 255 | 0.040 |
Why?
|
| Protein Transport | 1 | 2002 | 399 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2001 | 138 | 0.040 |
Why?
|
| Injections, Spinal | 2 | 2011 | 43 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 233 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 1280 | 0.040 |
Why?
|
| Illinois | 1 | 2020 | 14 | 0.040 |
Why?
|
| Mathematics | 1 | 2000 | 32 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 67 | 0.040 |
Why?
|
| Anesthetics, Local | 2 | 1990 | 69 | 0.040 |
Why?
|
| Genome | 3 | 2011 | 257 | 0.040 |
Why?
|
| Metalloendopeptidases | 2 | 1996 | 22 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2019 | 381 | 0.040 |
Why?
|
| DNA Replication | 1 | 2001 | 231 | 0.040 |
Why?
|
| Medical Records | 1 | 2020 | 141 | 0.040 |
Why?
|
| Antidiarrheals | 1 | 2019 | 2 | 0.040 |
Why?
|
| Travel Medicine | 1 | 2019 | 3 | 0.040 |
Why?
|
| Hepatitis A | 1 | 2019 | 8 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1999 | 31 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1998 | 14 | 0.040 |
Why?
|
| Staurosporine | 1 | 1998 | 19 | 0.040 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2018 | 3 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2002 | 318 | 0.040 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2018 | 5 | 0.040 |
Why?
|
| Receptors, Melatonin | 1 | 2018 | 34 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 1998 | 175 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 43 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 95 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 274 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 1995 | 5 | 0.040 |
Why?
|
| Regeneration | 1 | 2018 | 92 | 0.040 |
Why?
|
| Malaria | 1 | 2019 | 100 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 688 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2018 | 114 | 0.040 |
Why?
|
| Models, Biological | 1 | 2002 | 1150 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 285 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 342 | 0.030 |
Why?
|
| Ascites | 1 | 1996 | 21 | 0.030 |
Why?
|
| Phenylalanine | 1 | 1996 | 25 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2011 | 256 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 371 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 1996 | 48 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 2517 | 0.030 |
Why?
|
| Infusion Pumps | 2 | 1992 | 7 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 12 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1996 | 104 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 24 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2015 | 108 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 700 | 0.030 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 1994 | 3 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1995 | 62 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1994 | 14 | 0.030 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1994 | 12 | 0.030 |
Why?
|
| Neurites | 1 | 1994 | 22 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1994 | 20 | 0.030 |
Why?
|
| Axons | 1 | 1995 | 121 | 0.030 |
Why?
|
| Ion Channel Gating | 1 | 1994 | 44 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 1994 | 126 | 0.030 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 1994 | 7 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1994 | 17 | 0.030 |
Why?
|
| Glycerides | 1 | 1994 | 11 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 1994 | 51 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2014 | 12 | 0.030 |
Why?
|
| Glucuronides | 1 | 2014 | 11 | 0.030 |
Why?
|
| Canagliflozin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Bile | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cell Communication | 1 | 1994 | 127 | 0.030 |
Why?
|
| Meninges | 1 | 1994 | 10 | 0.030 |
Why?
|
| Nitroglycerin | 2 | 1990 | 12 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 160 | 0.030 |
Why?
|
| Tyrosine | 1 | 1994 | 94 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 71 | 0.030 |
Why?
|
| Heart Rate, Fetal | 1 | 1993 | 3 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1993 | 48 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1994 | 99 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 138 | 0.030 |
Why?
|
| Metoclopramide | 1 | 1993 | 12 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 334 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1993 | 145 | 0.030 |
Why?
|
| Nucleoside-Diphosphate Kinase | 1 | 1993 | 2 | 0.030 |
Why?
|
| Antibodies | 1 | 1993 | 180 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 652 | 0.030 |
Why?
|
| Labor, Induced | 1 | 1993 | 27 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1993 | 165 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 1993 | 64 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 154 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 358 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 314 | 0.030 |
Why?
|
| Foreign-Body Migration | 1 | 1992 | 20 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 572 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 1994 | 140 | 0.030 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2012 | 7 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2013 | 119 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 216 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2012 | 53 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2013 | 105 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 1993 | 37 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2012 | 109 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1992 | 70 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 119 | 0.020 |
Why?
|
| Neoplasms, Experimental | 2 | 1989 | 75 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 39 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 50 | 0.020 |
Why?
|
| Adipocytes | 1 | 1994 | 253 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 238 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 144 | 0.020 |
Why?
|
| Anesthesia | 1 | 2012 | 52 | 0.020 |
Why?
|
| Methotrexate | 1 | 2012 | 77 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1993 | 280 | 0.020 |
Why?
|
| Cardiac Catheterization | 2 | 1990 | 258 | 0.020 |
Why?
|
| Heart Rate | 1 | 1993 | 318 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 109 | 0.020 |
Why?
|
| Gelatinases | 3 | 1996 | 9 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 1991 | 14 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2012 | 246 | 0.020 |
Why?
|
| Umbilical Arteries | 1 | 1991 | 9 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Pituitary Hormones | 1 | 1990 | 4 | 0.020 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 63 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 848 | 0.020 |
Why?
|
| Procaine | 1 | 1990 | 2 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1990 | 30 | 0.020 |
Why?
|
| S100 Proteins | 1 | 1990 | 20 | 0.020 |
Why?
|
| Receptors, Opioid | 1 | 1990 | 14 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 236 | 0.020 |
Why?
|
| Pituitary Gland, Posterior | 1 | 1990 | 17 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 609 | 0.020 |
Why?
|
| Alfentanil | 1 | 1990 | 4 | 0.020 |
Why?
|
| Analgesia, Obstetrical | 1 | 1990 | 24 | 0.020 |
Why?
|
| Anesthesia Recovery Period | 1 | 1990 | 6 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 398 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1991 | 151 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 60 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1990 | 4 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 310 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 179 | 0.020 |
Why?
|
| Phospholipases | 1 | 1989 | 9 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 128 | 0.020 |
Why?
|
| Fetal Death | 1 | 1989 | 13 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1991 | 500 | 0.020 |
Why?
|
| Nerve Block | 1 | 1990 | 43 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 32 | 0.020 |
Why?
|
| Embolism, Air | 1 | 1989 | 9 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1989 | 8 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1989 | 53 | 0.020 |
Why?
|
| DNA Probes | 1 | 1989 | 35 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 1989 | 46 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1989 | 30 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 1989 | 47 | 0.020 |
Why?
|
| Appendicitis | 1 | 1990 | 75 | 0.020 |
Why?
|
| Epithelium | 1 | 1989 | 97 | 0.020 |
Why?
|
| Anesthesia, Inhalation | 1 | 1989 | 15 | 0.020 |
Why?
|
| Isoflurane | 1 | 1989 | 17 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 1989 | 98 | 0.020 |
Why?
|
| Succinylcholine | 1 | 1989 | 8 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 465 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 1990 | 96 | 0.020 |
Why?
|
| Oximetry | 1 | 1989 | 50 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1991 | 830 | 0.020 |
Why?
|
| Sheep | 1 | 1989 | 170 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2009 | 132 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 16 | 0.020 |
Why?
|
| Gestational Age | 1 | 1989 | 186 | 0.020 |
Why?
|
| Gene Expression | 3 | 1998 | 815 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1990 | 216 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 651 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 144 | 0.020 |
Why?
|
| Health Behavior | 1 | 2011 | 473 | 0.020 |
Why?
|
| Biopsy | 1 | 1989 | 408 | 0.020 |
Why?
|
| Neutrophils | 1 | 1990 | 353 | 0.020 |
Why?
|
| Calcium | 1 | 1990 | 560 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 703 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1060 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2004 | 1996 | 0.020 |
Why?
|
| Software Validation | 1 | 2005 | 8 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1989 | 1326 | 0.020 |
Why?
|
| Quipazine | 1 | 1984 | 1 | 0.010 |
Why?
|
| Aging | 1 | 1990 | 739 | 0.010 |
Why?
|
| Prolactin | 1 | 1984 | 40 | 0.010 |
Why?
|
| Quinolines | 1 | 1984 | 41 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1984 | 98 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1984 | 99 | 0.010 |
Why?
|
| Dopamine | 1 | 1984 | 101 | 0.010 |
Why?
|
| Pargyline | 1 | 1982 | 2 | 0.010 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1982 | 3 | 0.010 |
Why?
|
| Hydrazines | 1 | 1982 | 10 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1982 | 11 | 0.010 |
Why?
|
| Isotopes | 1 | 2002 | 6 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1125 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2002 | 49 | 0.010 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2002 | 2 | 0.010 |
Why?
|
| Calpain | 1 | 2002 | 6 | 0.010 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2002 | 7 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 1982 | 129 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 21 | 0.010 |
Why?
|
| Software | 1 | 2005 | 379 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2002 | 26 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 19 | 0.010 |
Why?
|
| Neocortex | 1 | 2001 | 15 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 62 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2002 | 41 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 34 | 0.010 |
Why?
|
| United States | 1 | 2014 | 7657 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2001 | 26 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 380 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 169 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 334 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1605 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 252 | 0.010 |
Why?
|
| Milk Proteins | 1 | 2000 | 45 | 0.010 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1998 | 7 | 0.010 |
Why?
|
| Mitochondria | 1 | 2002 | 342 | 0.010 |
Why?
|
| Karyotyping | 1 | 1998 | 44 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1998 | 85 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 607 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 1998 | 78 | 0.010 |
Why?
|
| Transgenes | 1 | 1998 | 175 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2080 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1995 | 5 | 0.010 |
Why?
|
| Receptors, Somatomedin | 1 | 1996 | 10 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1995 | 11 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 1996 | 41 | 0.010 |
Why?
|
| Gelatin | 1 | 1995 | 29 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 117 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1996 | 214 | 0.010 |
Why?
|
| Factor VIII | 1 | 1993 | 32 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1993 | 18 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1993 | 54 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1993 | 64 | 0.010 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 1993 | 7 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 34 | 0.010 |
Why?
|
| Collagen | 1 | 1993 | 118 | 0.010 |
Why?
|
| Pepsin A | 1 | 1993 | 6 | 0.010 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 1993 | 3 | 0.010 |
Why?
|
| Cathepsin D | 1 | 1993 | 11 | 0.010 |
Why?
|
| Receptors, Laminin | 1 | 1993 | 17 | 0.010 |
Why?
|
| Collagenases | 1 | 1993 | 14 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1993 | 81 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 112 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1993 | 156 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1993 | 59 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1993 | 223 | 0.010 |
Why?
|
| Spleen | 1 | 1993 | 486 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1993 | 451 | 0.010 |
Why?
|
| Estradiol | 1 | 1993 | 246 | 0.010 |
Why?
|
| Butorphanol | 1 | 1990 | 4 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1993 | 280 | 0.010 |
Why?
|
| Receptors, Opioid, mu | 1 | 1990 | 15 | 0.010 |
Why?
|
| Lidocaine | 1 | 1990 | 30 | 0.010 |
Why?
|
| Preanesthetic Medication | 1 | 1990 | 2 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1990 | 25 | 0.010 |
Why?
|
| Computers | 1 | 1990 | 50 | 0.010 |
Why?
|
| Ketones | 1 | 1990 | 5 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1990 | 18 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 174 | 0.010 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1989 | 6 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1989 | 65 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1989 | 34 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1990 | 168 | 0.010 |
Why?
|
| Veins | 1 | 1989 | 61 | 0.000 |
Why?
|
| Random Allocation | 1 | 1989 | 199 | 0.000 |
Why?
|
| Intraoperative Complications | 1 | 1989 | 83 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 757 | 0.000 |
Why?
|
| Methyltyrosines | 1 | 1984 | 2 | 0.000 |
Why?
|
| alpha-Methyltyrosine | 1 | 1984 | 2 | 0.000 |
Why?
|
| Caudate Nucleus | 1 | 1984 | 25 | 0.000 |
Why?
|
| Hypothalamus | 1 | 1984 | 118 | 0.000 |
Why?
|
| Nucleus Accumbens | 1 | 1984 | 42 | 0.000 |
Why?
|
| Potassium | 1 | 1984 | 110 | 0.000 |
Why?
|